American Century Companies Inc. Has $43.76 Million Position in Ionis Pharmaceuticals, Inc. (IONS)
American Century Companies Inc. cut its stake in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) by 0.2% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 860,260 shares of the company’s stock after selling 1,697 shares during the period. American Century Companies Inc. owned approximately 0.69% of Ionis Pharmaceuticals worth $43,761,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors have also recently made changes to their positions in IONS. Hanseatic Management Services Inc. bought a new position in Ionis Pharmaceuticals during the first quarter worth approximately $138,000. Sei Investments Co. increased its position in Ionis Pharmaceuticals by 11.1% in the first quarter. Sei Investments Co. now owns 40,237 shares of the company’s stock worth $1,618,000 after buying an additional 4,030 shares during the period. Karp Capital Management Corp bought a new position in Ionis Pharmaceuticals during the first quarter worth approximately $687,000. UBS Asset Management Americas Inc. increased its position in Ionis Pharmaceuticals by 3.5% in the first quarter. UBS Asset Management Americas Inc. now owns 318,360 shares of the company’s stock worth $12,798,000 after buying an additional 10,877 shares during the period. Finally, World Asset Management Inc increased its position in Ionis Pharmaceuticals by 27.3% in the first quarter. World Asset Management Inc now owns 5,427 shares of the company’s stock worth $218,000 after buying an additional 1,163 shares during the period. Institutional investors and hedge funds own 89.32% of the company’s stock.
Shares of Ionis Pharmaceuticals, Inc. (NASDAQ IONS) opened at 48.86 on Wednesday. The firm has a market capitalization of $6.08 billion, a PE ratio of 234.90 and a beta of 3.14. The firm’s 50 day moving average is $50.97 and its 200-day moving average is $47.20. Ionis Pharmaceuticals, Inc. has a one year low of $24.58 and a one year high of $60.01.
Ionis Pharmaceuticals (NASDAQ:IONS) last released its earnings results on Tuesday, August 8th. The company reported ($0.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.06) by $0.03. The company had revenue of $104.15 million for the quarter, compared to analyst estimates of $93.29 million. Ionis Pharmaceuticals had a return on equity of 15.52% and a net margin of 5.25%. The business’s revenue for the quarter was up 170.7% compared to the same quarter last year. During the same period last year, the company posted ($0.47) earnings per share. On average, equities research analysts predict that Ionis Pharmaceuticals, Inc. will post ($0.19) earnings per share for the current fiscal year.
ILLEGAL ACTIVITY WARNING: “American Century Companies Inc. Has $43.76 Million Position in Ionis Pharmaceuticals, Inc. (IONS)” was originally published by Watch List News and is the sole property of of Watch List News. If you are accessing this story on another publication, it was illegally stolen and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this story can be viewed at https://www.watchlistnews.com/american-century-companies-inc-has-43-76-million-position-in-ionis-pharmaceuticals-inc-ions/1531494.html.
IONS has been the topic of a number of research analyst reports. Piper Jaffray Companies set a $51.00 price objective on shares of Ionis Pharmaceuticals and gave the company a “buy” rating in a research note on Wednesday, May 10th. BMO Capital Markets increased their price objective on shares of Ionis Pharmaceuticals from $32.00 to $35.00 and gave the company an “outperform” rating in a research note on Thursday, May 11th. Needham & Company LLC reiterated a “buy” rating and set a $64.00 price objective on shares of Ionis Pharmaceuticals in a research note on Wednesday, May 17th. Leerink Swann reiterated an “outperform” rating and set a $45.00 price objective (down from $47.00) on shares of Ionis Pharmaceuticals in a research note on Wednesday, May 17th. Finally, Cowen and Company reiterated a “market perform” rating on shares of Ionis Pharmaceuticals in a research note on Monday, May 22nd. Three equities research analysts have rated the stock with a sell rating, six have assigned a hold rating and seven have given a buy rating to the stock. Ionis Pharmaceuticals currently has a consensus rating of “Hold” and a consensus target price of $48.91.
In related news, major shareholder Ionis Pharmaceuticals Inc bought 3,125,000 shares of Ionis Pharmaceuticals stock in a transaction dated Wednesday, July 19th. The shares were bought at an average cost of $8.00 per share, with a total value of $25,000,000.00. Following the acquisition, the insider now owns 28,884,540 shares in the company, valued at approximately $231,076,320. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP C Frank Bennett sold 10,000 shares of the stock in a transaction on Monday, July 24th. The stock was sold at an average price of $59.29, for a total value of $592,900.00. Following the sale, the senior vice president now directly owns 25,041 shares in the company, valued at $1,484,680.89. The disclosure for this sale can be found here. Over the last three months, insiders have sold 54,379 shares of company stock worth $2,946,052. 1.86% of the stock is currently owned by insiders.
Ionis Pharmaceuticals Company Profile
Ionis Pharmaceuticals, Inc is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company, using its drug discovery platform, has developed a pipeline of drugs for patients with unmet medical needs. The Company’s segments include Ionis Core and Akcea Therapeutics. In the Ionis Core segment, the Company is engaged in exploiting a drug discovery platform to generate a pipeline of drugs for the Company and its partners.
Want to see what other hedge funds are holding IONS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ionis Pharmaceuticals, Inc. (NASDAQ:IONS).
Receive News & Ratings for Ionis Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.